The case involves a regulatory issue — whether the FDA's approval of abortion pill mifepristone, and subsequent actions making it easier to obtain, must be rolled back.
, will hear arguments May 17 on whether a widely used abortion drug should remain available.
The Supreme Court on April 21, 2023, preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues. The justices granted emergency requests from the Biden administration and New York-based Danco Laboratories, maker of the drug mifepristone.
That same year, she wrote for a panel that refused to order Louisiana to issue a long-stalled license for a Planned Parenthood abortion clinic in New Orleans, saying "there is no free-standing federal right to receive an abortion-clinic license." When the full court narrowly refused to let Louisiana officials cut off Medicaid funding for Planned Parenthood facilities in the state, Elrod wrote the dissent.
He went on to cite "the racial history of abortion advocacy as a tool of the eugenics movement." He harshly criticized a lower court for declining to consider arguments that a fetus can feel pain, and for displaying "an alarming disrespect for the millions of Americans who believe ... that abortion is the immoral, tragic, and violent taking of innocent human life."Cory Wilson
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA Clears Renuvion APR Handpiece for Use After LiposuctionThe agency’s update on Wednesday follows three updates on the Renuvion/J-Plasma system in 2022.
Baca lebih lajut »
FDA approves first-of-its-kind drug to treat hot flashesThe FDA has approved a first-of-its-kind drug to treat moderate to severe hot flashes during menopause.
Baca lebih lajut »
FDA Moves to Curb Misuse of ADHD MedsThe FDA has unveiled fresh measures aimed at tackling persistent worries surrounding the improper use, abuse, addiction, and overdose of prescription stimulants prescribed for ADHD treatment. TwitteRx
Baca lebih lajut »
Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapySarepta Therapeutics Inc.’s stock soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6 in favor of accelerated approval for...
Baca lebih lajut »
FDA issues notice for recalled baby formula distributed out of NashvilleRECALL: This recalled product was distributed from its Nashville Division only to independent retailers located in Alabama, Georgia, Indiana, Kentucky, Ohio, Tennessee, Virginia, and West Virginia.
Baca lebih lajut »